Titanium and rare earths play Resouro set to fire away
Special Report: There’s a critical mineral that’s been flying well below the radar – even though it’s literally right under our noses and is in [more…]
Top 10 at 10: This scorching hot explorer is up 200% in a week
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. [more…]
Market Highlights: ASX to lift on the back of Nasdaq rally; and 5 small caps to watch today
ASX to lift on the back of Nasdaq rally US stocks rose on Friday as big techs reported solid results The US PCE Index [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 29 April, 2024 – an important date in the history of having a gossip on the phone, as [more…]
Long Shortz with Felix Gold: Exploration heating up in Alaska’s Fairbanks district
Stockhead’s Sarah Hughan sits down with Felix Gold (ASX:FXG) executive director Joseph Webb to get the short end of the long story on the company’s latest news. [more…]
Traders’ Diary: Everything you need to get ready for the week ahead
What grabbed the headlines last week? Wall Street was delivered a tinely reminder last week of the power of 7. Emphastic earnings reports from [more…]
WA’s Prospector Laureate has had another big year. Where else could Mark Creasy strike it rich?
Mark Creasy is set to net over $200 million from his stake in Azure Minerals if a takeover deal goes ahead The one prospector to [more…]
Aroa Biosurgery to target US$300 million trauma market with Myriad products
Aroa Biosurgery expects its Myriad portfolio to continue driving strong growth in the soft tissue reconstruction market Initially focus on trauma segment of market, which [more…]
Hot Money Monday: Expert says buying stock at 52-week high is better than ‘buy low – sell high’ strategy
Buying a stock at its 52-week highs can be counterintuitive for many investors because it goes against the traditional idea of buying low and selling [more…]
Dr Boreham’s Crucible: In rare Phase 3 air, can Opthea now see its way clear to a $15bn market?
One doesn’t have to be a Madison Avenue ‘Mad Man’ to know that it’s more effective to have a credible third party spruik a product [more…]
